Epidemiological evidence from retrospective studies indicates an association between CYP2D6 variations and altered tamoxifen response in a range of therapeutic settings such as metastatic breast cancer [28], cancer prevention [29], and adjuvant therapy [17], [18], [20], [21]. The gene discussed is CYP2D6; the disease is cancer.